Winway Health Desk
Genfit delays data from Phase III study of NASH drug as...
Shares of one of the companies potentially close to having a therapy on the market for nonalcoholic steatohepatitis fell Friday after the firm said...
Puma Biotech’s Nerlynx remains a dud. Will a breast cancer expansion...
Sales of Puma Biotech’s only commercial product—breast cancer drug Nerlynx—still need improvement, company chief Alan Auerbach acknowledged. But as one analyst sees it, a label...
‘Boring is good,’ Teva CEO Schultz says amid push to hit...
Teva’s CEO Kåre Schultz had his hands full when he joined the company back in 2017, and while the drugmaker still faces significant challenges, he's...
Sleep Apnea with Down Syndrome: New Treatment Shows Promise
More than half of children and almost all adults who have Down syndrome struggle with obstructive...
Gilead loses again in PrEP patent fight with HHS, sending dispute...
In its high-profile patent feud with the U.S. government over HIV prevention medicines, Gilead Sciences has suffered its second consecutive loss.
Following a similar decision earlier this month,...
FiercePharmaAsia—Coronavirus’s impact on AstraZeneca, global drug supply; vadadustat PRV
Although the novel coronavirus has not caused any drug shortages, health regulators around the globe are preparing for potential disruptions as the outbreak drags...
Fitbit profits fall ahead of pending Google merger
Awaiting approval for its $2.1 billion merger with Google’s parent company, Fitbit saw its profits drop in 2019 as its customers turned to cheaper...
Make-A-Wish partners help grant more wishes every year
This article is the result of a partnership between MedCity News and Make-A-Wish Foundation.
In the spring of 1980, Make-A-Wish granted its first wish to a 7-year-old...
Startup bringing gig-economy approach to nurse staffing raises $45M
IntelyCare’s app matches nurses with nearby shifts, helping fill shortages at long-term care facilities.
A startup bringing a tech-based approach to healthcare staffing raised $45...
Another company took an old drug and jacked up the price....
Former Turing Pharma CEO Martin Shkreli may be the favorite whipping boy for outrage over companies that drastically raise drug prices, but a group...
